Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers

Annals of the New York Academy of Sciences

Volumn 1174, Issue , 2009, Pages 41-50

  Mann, Dean L ^a   Celluzzi, Christina M ^a   Hankey, Kim G ^a   Harris, Kristina M ^a   Watanabe, Ryuko ^b   Hasumi, Kenichiro ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Hasumi International Research Foundation   (Japan)

Author keywords

Activated T cells; Cancer vaccine; Combination immunotherapy; Dendritic cells; Intratumoral injection

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PORIA COCOS EXTRACT; HLA DR ANTIGEN; LEUKOCYTE ANTIGEN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL CULTURE; CELL THERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; RADIATION DOSE; RATING SCALE; T LYMPHOCYTE; ANTIGEN PRESENTING CELL; ARTICLE; AUTOTRANSPLANTATION; BREAST TUMOR; COLORECTAL TUMOR; CULTURE MEDIUM; GENETICS; IMMUNOLOGY; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MULTIMODALITY CANCER THERAPY; NEOPLASM; STOMACH TUMOR; TRANSPLANTATION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CULTURE MEDIA, CONDITIONED; DENDRITIC CELLS; FEMALE; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; NEOPLASMS; STOMACH NEOPLASMS; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS;

EID: 70350509311     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04934.x     Document Type: Conference Paper

References (44)

1. Banchereau, J. et al. 2003. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann. N T.Acad. Sci 987: 180-187. (Pubitemid 36584021)
2. Banchereau, J & R.M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
3. Steinman, R.M. et al. 1999. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum. Immunol. 60: 562-567.
4. den Brok, M.H. et al. 2005. Dendritic cells: tools and targets for antitumor vaccination. Expert Rev. Vaccines 4: 699-710. (Pubitemid 41530593)
5. Paczesny, S. et al. 2003. Dendritic cells as vectors for immunotherapy of cancer. Semin. Cancer Biol. 13: 439-447. (Pubitemid 38156136)
6. Small, E.J. et al. 2000. Immunotherapy of hormonerefractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18: 3894-3903.
7. Bodey, B. et al. 2000. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 20: 2665-2676. (Pubitemid 30614482)
8. Hsu, F.J. et al. 1996. Vaccination of patients with Bcell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2: 52-58.
9. Chi, K.H. et al. 2005. Combination of conformai radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J. Immunother. 28: 129-135.
10. Morse, M.A. et al. 2003. Immunotherapy with autologous, human dendritic cells transfected with cancinoembryonic antigen mRNA. Cancer Invest. 21: 341349.
11. Hoffmann, T.K. et al. 2000. Generation of tumorspecific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 60: 3542-3549.
12. Tanaka, F. et al. 2002. Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. Int. J. Cancer 101: 265-269. (Pubitemid 34970895)
13. Tong, Y., W Song & R.G. Crystal. 2001. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat preexisting murine tumors. Cancer Res. 61: 7530-7535. (Pubitemid 32995044)
14. Triozzi, PL. et al. 2000. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89: 2646-2654.
15. Hodi, ES. &G. Dranoff. 2006. Combinatorial cancer immunotherapy. Adv. Immunol. 90: 341-368.
16. Srivastava, P.K. 2003. Hypothesis: controlled necrosis as a tool for immunotherapy of human cancer. Cancer Immun. 3: 4.
17. Dieu-Nosjean, M.C. et al. 1999. Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. J. Leukoc. Biol. 66: 252-262.
18. Hatfield, P. et al. 2005. Radiation-induced cell death and dendritic cells: potential for cancer immunotherapy? Clin. Oncol. (R. Coll. Radiol.) 17: 1-11. (Pubitemid 39665237)
19. Restifo, N.P. 2000. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr. Opin. Immunol. 12: 597-603.
20. Berd, D., H.C Maguire, Jr. & M.J. Mastrangelo. 1984. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res. 44: 5439-5443. (Pubitemid 15204525)
21. Greenberg, P.D., M.A. Cheever & A. Fefer. 1981. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1 + 2lymphocytes. J. Exp. Med. 154: 952-963.
22. Awwad, M. & R.J. North. 1989. Cyclophosphamideinduced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res. 49: 1649-1654. (Pubitemid 19108381)
23. Ghiringhelli, F. et al. 2004. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344. (Pubitemid 39255944)
24. Berger, C et al. 2003. CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy. Blood 101: 476-484. (Pubitemid 36077568)
25. Grimm, E. A. et al. 1982. Lymphokine-activated killercell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155: 1823-1841.
26. Laport, G.G. et al. 2003. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 102: 2004-2013.
27. Levine, B.L. et al. 2002. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat. Med. 8: 47-53.
28. Levine, B.L. et al. 1997. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in tlie absence of exogenous feeder cells, J, Immunol. 159: 5921-5930.
29. Maus, M.V., et al. 2002. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB, Nat. Biotecknol. 20 143-148.
30. Rapoport, A.P, et al. 2004, Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells, Bone Marrow Transplant. 33: 53-60,
31. Thompson, J.A, et al. 2003. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma, Clin. Cancer Res. 9i 3562-3570, (Pubitemid 37169219)
32. Yamazaki, T, & T, Sekine, 1992. Characterization of immobilized anti-CD3 antibody-activated T lymphocytes for use in adoptive immunotherapy of patients with brain tumors, Neurol. Med. Chir. (Tokyo). 321 255-261.
33. Yee, C. 2005. Adoptive T cell therapy: Addressing challenges in cancer immunotherapy, J. Transi. Med. 3: 17. (Pubitemid 41522089)
34. Sato, T. et al. 2004, Combination of monocytederived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy, Cancer Immunol. Immunother. 53: 53-61,
35. Goldrath, A.W. & MJ. Bevan. 1999. Selecting and maintaining a diverse T-cell repertoire, Nature 4021 255-262.
36. Harris, K.M. et al. 2008, Products of anti-CD 3/antiCD 2 8 activated lymphocytes induce differentiationand maturation of dendritic cells and have adjuvantlike activity in vitro and in vivo, Clin. Immunol. 129i 58-68.
37. Pécher, G. et al. 2002. Mucin gene (MUCl) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol. Immunother. 51i 669-673, (Pubitemid 35446294)
38. Henry, F. et al. 1999, Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines, Cancer Res. 59, 3329-3332, (Pubitemid 29334486)
39. Jenne, L, et al. 2000, Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis, Cancer Res, 6Oi 44464452, (Pubitemid 32103624)
40. Schnurr, M. et al. 2002. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting crosspriming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res. 62, 2347-2352. (Pubitemid 34411716)
41. Dynlacht, J.R. et al. 1999, Degradation of the nuclear matrix is a common element during radiationinduced apoptosis and necrosis, Radiât Res. 152, 590-603.
42. Shinomiya, N, et al. 2000, Different mechanisms between premitotic apoptosis and postmitotic apoptosis in X-irradiated U937 cells. Int. J. Radia Oncol. Biol Phys. 47, 767-777. (Pubitemid 30317498)
43. Stahnke, K, et al. 2001, Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy, Blood 98: 3066-3073,
44. Kudo-Saito, C. et al. 2005, The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors, Clin. Cancer Res. Hi 4533-4544. (Pubitemid 40825644)